Cambridge - Generate:Biomedicines today announced key advancements across its clinical pipeline and generative AI platform, including its first patient dosed in GB-0895, progress in the phase 1 study for GB-0669, and an expansion of its collaboration agreement with
'In 2023, we saw meaningful advances in our computational and experimental capabilities that are shaping the era of generative biology, and in the year ahead we are poised to fortify our leadership in the field,' said
Advancing Clinical Pipeline
Generate:Biomedicines will provide an overview of key milestones and progress across its differentiated clinical pipeline, as well as its plans to deliver an additional 4-5 assets to the clinic over the next 24 months, including: Successfully dosed first patient in the study of GB-0895, an anti-TSLP monoclonal antibody for the treatment of mild-to-moderate asthma, in the
Continuing to progress the phase 1 study for GB-0669, a monoclonal antibody targeting the S2 stem helix, a highly conserved region of spike protein in SARS-CoV-2. Safety has been shown for the first four of five planned cohorts, including the putative recommended dose; analysis of key biomarkers is ongoing. GB-0669 continues to show potent in vitro neutralization of all major variants tested to date.
Industry Leading Generative AI Platform
The company will also share ongoing efforts to advance its leadership position in the application of AI to therapeutic discovery and development with The Generate Platform, for example: Applying multiparameter co-optimization across its broad pipeline, successfully generating multiple assets with best-in-class profiles. This includes scaling the platform in immunology with a highly potent anti-IL-13 monoclonal antibody for certain type-2 inflammation-mediated diseases, such as atopic dermatitis and an anti-hemagglutinin (HA) monoclonal antibody targeting influenza.
Generating de novo binders (e.g., molecules generated entirely by the computer and without a template) in order to unlock historically undruggable or hard-to-drug targets with controllable specificity. By enabling superior de novo hit rates, the company continues to pioneer the generation and validation of de novo antibodies, and this has now been demonstrated across nine distinct targets.
Deploying structure in the learning loop utilizing CryoEM to generate data for iterative learning which has shown faster, improved outcomes.
Expanding
Generate:Biomedicines will highlight the expansion of its existing collaboration agreement with
'Through our expanded collaboration, we will continue bringing
About Generative Biology
Generative biology represents a fundamental shift in therapeutic development driven by generative artificial intelligence (AI). This approach creates never-before-seen therapeutic molecules targeted to specific biological processes involved in disease that can be modulated with a wide range of protein modalities-from short peptides to complex antibodies, enzymes, and cytokines. But the promise of generative biology goes beyond existing proteins found in nature and can create novel proteins that are purpose-built to address an existing or emerging therapeutic need. As a result, generative biology promises to leave trial-and-error drug discovery methods behind to usher in a new era of programmable drug generation that's faster, cheaper, and better tailored to specific conditions.
About Generate:Biomedicines
Generate:Biomedicines is the first drug generation company pioneering a machine learning-powered generative biology platform with the ability to create new drugs on demand across a wide range of biologic modalities. The Generate Platform - which is a continuous loop to generate, build, measure, and learn - can drastically increase the speed at which targets and therapeutics are identified and validated. This will improve the specificity of target engagement by generated proteins and reduce the time and cost of identifying and developing clinical candidates. Generate:Biomedicines is a clinical stage company that was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.
Contact:
Email: pr@generatebiomedicines.com
(C) 2024 Electronic News Publishing, source